Marina Pipeline on Track with FAP Trial in 2010, But Could Miss Partnership Guidance | GenomeWeb

By Doug Macron

Officials from Marina Biotech last week reported that the company remains on track to begin the first part of a phase Ib/IIa trial of its oral familial adenomatous polyposis treatment CEQ508 before the year is out, and that its program in bladder cancer is expected to yield an investigational new drug application in 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."